Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines

By Rajashekhar G.   Loganath A.   Roy A.C.   Mongelli J.M.  

Gynecologic Oncology, Vol. 91, Iss. 1, 2003-10 ,pp. : 101-111

Elsevier

Access to resources Recommend Favorite

Fas expression in non-small cell lung cancer - a preliminary report

By Uramoto H.   Osaki T.   Inoue M.   Taga S.   Takenoyama M.   Hanagiri T.   Yoshino I.   Nakanishi R.   Ichiyoshi Y.   Yasumoto K.  

European Journal of Cancer, Vol. 35, Iss. 10, 1999-10 ,pp. : 1462-1465

Elsevier

Access to resources Recommend Favorite

Activation of Fas Ligand/Receptor System Kills Ovarian Cancer Cell Lines by an Apoptotic Mechanism

By Ghahremani M.   Foghi A.   Dorrington J.H.  

Gynecologic Oncology, Vol. 70, Iss. 2, 1998-08 ,pp. : 275-281

Elsevier

Access to resources Recommend Favorite

Isolinderalactone inhibits proliferation of A549 human nonsmall cell lung cancer cells by arresting the cell cycle at the G0/G1 phase and inducing a Fas receptor and soluble Fas ligand-mediated apoptotic pathway

By          

Molecular Medicine Reports, Vol. 9, Iss. 5, 2014-01 ,pp. : 1653-1659

Spandidos Publications

Access to resources Recommend Favorite

Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo

By Perabo F.G.E.   Mattes R.H.   Wirger A.   Steiner G.   Kamp S.   Schmidt D.   Pegelow K.   von Ruecker A.   Muller S.C.  

Urologic Oncology: Seminars and Original Investigations, Vol. 6, Iss. 4, 2001-07 ,pp. : 163-169

Elsevier

Access to resources Recommend Favorite